Experienced in Delayed Growth

Alexander J. Stein

Eppendorf, HH, DE 
Experienced in Delayed Growth
Eppendorf, HH, DE 
OverviewLocationsClinical Research

Overview

Alexander Stein practices in Eppendorf, Germany. Mr. Stein is rated as an Experienced expert by MediFind in the treatment of Delayed Growth. His top areas of expertise are Colorectal Cancer, Hairy Cell Leukemia (HCL), Febrile Neutropenia, Bone Marrow Transplant, and Gastrectomy.

His clinical research consists of co-authoring 123 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Delayed Growth.

Gender
Male

Locations

Eppendorf, HH, Germany
Other Locations
Hamburg, HH, Germany
Goettingen, NI, Germany
Halle, NI, Germany
Breisacher Str, 117, Freiburg, BW 79106, Germany
Hannover, NI 30167, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

Adjuvant Aspirin Treatment in PIK3CA Mutated Colon Cancer Patients. A Randomized, Double-blinded, Placebo-controlled, Phase III Trial
Adjuvant Aspirin Treatment in PIK3CA Mutated Colon Cancer Patients. A Randomized, Double-blinded, Placebo-controlled, Phase III Trial
Enrollment Status: Terminated
Publish Date: May 16, 2025
Intervention Type: Drug
Study Drug: Aspirin
Study Phase: Phase 3
An Open-label 2:1 Randomized Phase II Study of Panitumumab Plus FOLFOXIRI or FOLFOXIRI Alone as First-line Treatment of Patients With Non-resectable Metastatic Colorectal Cancer and RAS Wild Type
An Open-label 2:1 Randomized Phase II Study of Panitumumab Plus FOLFOXIRI or FOLFOXIRI Alone as First-line Treatment of Patients With Non-resectable Metastatic Colorectal Cancer and RAS Wild Type
Enrollment Status: Completed
Publish Date: June 15, 2023
Intervention Type: Drug
Study Phase: Phase 2
Personalized Marker-driven Early Switch to Aflibercept in Patients With Metastatic Colorectal Cancer (PERMAD-Trial) - a Multicenter, Multinational, Two Part, Phase II Trial
Personalized Marker-driven Early Switch to Aflibercept in Patients With Metastatic Colorectal Cancer (PERMAD-Trial) - a Multicenter, Multinational, Two Part, Phase II Trial
Enrollment Status: Unknown
Publish Date: September 20, 2019
Intervention Type: Biological
Study Phase: Phase 2
View 2 Less Clinical Trials

123 Total Publications

Zanzalintinib plus atezolizumab versus regorafenib in refractory colorectal cancer (STELLAR-303): a randomised, open-label, phase 3 trial.
Zanzalintinib plus atezolizumab versus regorafenib in refractory colorectal cancer (STELLAR-303): a randomised, open-label, phase 3 trial.
Journal: Lancet (London, England)
Published: August 29, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Stein's expertise for a condition
ConditionClose
    View All 23 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile